Showing 3501-3510 of 19348 results for "".
Evidence-Based Guidelines for Managing Acne: Updates from AAD
https://reachmd.com/programs/clinicians-roundtable/evidence-based-guidelines-for-managing-acne-updates-from-aad/30057/The 2024 AAD guidelines provide updates and evidence-based recommendations for treating acne to improve patient outcomes. Here’s an overview.Case-Based Management of AAV
https://reachmd.com/programs/cme/case-based-management-of-aav/14963/Given the unmet needs in AAV treatment with glucocorticoids, there may be a role for complement receptor inhibition. Hear more from our experts!Cases From the Real World: 72-Year-Old Woman With CRVO
https://reachmd.com/programs/cme/Cases-From-the-Real-World-72-Year-Old-Woman-With-CRVO/33171/Hear how Drs. Ferhina Ali and Yasha Modi navigate the balance of extending treatment intervals while reducing the risk of recurrent ME in RVO.Advancing Clinical Expertise in CELMoDs: Transforming Multiple Myeloma Treatment
https://reachmd.com/programs/cme/advancing-clinical-expertise-in-celmods-transforming-multiple-myeloma-treatment/35631/This activity will cultivate familiarity with the emerging CELMoD treatment class poised to transform the management of newly-diagnosed and R/R MM. With a higher affinity for cereblon than their predecessors, CELMoDs represent a new, distinct generation of immunomodulatory drugs with the potential tDecoding EGPA: A Clinical Deep Dive Into Diagnosis and Treatment
https://reachmd.com/programs/cme/decoding-egpa-a-clinical-deep-dive-into-diagnosis-and-treatment/54493/On-demand webcast on the latest advances in diagnosing and managing patients with eosinophilic granulomatosis with polyangiitis (EGPA), including current data on new EGPA therapies and shared decision-making strategies to help patients achieve and maintain remission.Rethinking Schizophrenia Treatment Through Muscarinic Modulation
https://reachmd.com/programs/cme/rethinking-schizophrenia-treatment-through-muscarinic-modulation/37103/Learn expert insights on muscarinic antipsychotics in schizophrenia, including mechanisms, safety, and switching considerations.Emerging Clinical Evidence for B7-H3–Directed ADCs in ES-SCLC From ESMO 2025
https://reachmd.com/programs/cme/emerging-clinical-evidence-for-b7-h3directed-adcs-in-es-sclc-from-esmo-2025/39978/Explore recent clinical data on B7-H3 ADCs in ES-SCLC, with expert insights on biological rationale, efficacy outcomes, safety profiles, and patient selection.Guideline Recommendations in First-Line Treatment of HER2-Negative Upper GI Cancers
https://reachmd.com/programs/cme/guideline-recommendations-in-first-line-treatment-of-her2-negative-upper-gi-cancers/37689/Partnering with Patients: Improving First-Line Treatment Selection in Upper GI Cancers Through Shared Decision-MakingPsoriasis and Obesity: Going Pound for Pound on Comprehensive, Patient-Centered Management
https://reachmd.com/programs/cme/psoriasis-and-obesity-going-pound-for-pound-on-comprehensive-patient-centered-management/39671/On-demand webcast of expert faculty presentation on the key connection between psoriasis and obesity, including comprehensive treatment strategies that consider outcomes improvement for both diseases.Early aggressive lipid-lowering strategy with PCSK9 siRNA performs better than usual care in US patients with ASCVD
https://reachmd.com/programs/acc-action-center/early-aggressive-lipid-lowering-strategy-with-PCSK9-siRNA-performs-better-than-usual-care-in-us-patients-with-ascvd/24289/ACC.24 - A structured approach to treat hypercholesterolemia with an "inclisiran first" strategy in US patients with ASCVD performs much better than usual care, according to Michael Koren. He hopes that the results of VICTORION-INITIATE are a wake-up call to treat patients more aggressively with lip